Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicinePhase 2 Trial of Baxdrostat for Treatment-resistant Hypertension

248 patients with blood pressures of 130/80 mm Hg or higher despite treatment with at least three antihypertensive agents were randomized to baxdrostat once daily for 12 weeks vs. placebo. The aldosterone synthase inhibitor generated dose-related reductions in blood pressure of 8 to 11 mmHg vs. placebo.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form